FRISQ Care will be used for rehabilitation after common form of cancer
FRISQ Care will be used in collaboration with renowned Professor Anna Martling at Karolinska Institutet (KI), one of the world’s foremost medical universities, to study new methods for improving the rehabilitation of patients with colorectal cancer.
Karolinska Institutet has attained a license to offer FRISQ Care to selected patient in the rehabilitation process following the treatment of colorectal cancer – the third most common cause of deadly cancer, with over 6,000 new diagnosed cases in Sweden annually. The purpose of the collaboration is to provide support to patients in their rehabilitation, continuous evaluation of new treatment methods and to communicate information between researchers and patients.
Earlier this year, Anna Martling was awarded Tarmcancerpriset (the Bowel Cancer Prize) for her research, which has contributed to revolutionary changes in the treatment of colorectal cancer both nationally and internationally.
“We are proud that Anna Martling and KI have chosen to collaborate with FRISQ in this research project. We believe that the tool will be able to reduce the threshold between cutting-edge research and regular care. Today, it takes time for innovations to spread, but through FRISQ Care it will be much easier to share “best practice” and equal care between businesses”, says Martin Irding CEO at FRISQ.
Within the project, FRISQ Care will serve as a tool for communicating with, and supporting patients undergoing rehabilitation – and thus be used by both healthcare professionals and patients.